Private Eylea HD 8mg wet AMD injection cost

Private Eylea HD 8mg costs £1,250–£1,900 per injection all-inclusive at CQC-registered UK medical retina centres in 2026. That bundles the drug vial, the sterile clean-injection room, your consultant’s professional fee, OCT imaging on the day and a 1–2 week safety check. A typical year-1 loading-plus-extension course (5–8 injections) runs £7,500–£13,300, and a steady-state year-2 course (3–4 injections at 12–16 week intervals) runs £3,750–£7,600. Eylea HD is not cheaper per dose than standard 2mg aflibercept, but the total year-2 cost is often lower because you need fewer injections.

What is Eylea HD and why does the 8mg dose matter?

Eylea HD is a higher-strength formulation of aflibercept, a recombinant fusion protein that binds vascular endothelial growth factor (VEGF-A and VEGF-B) and placental growth factor (PlGF). Standard Eylea contains 2mg aflibercept per 0.05ml; Eylea HD contains 8mg in 0.07ml at a 4-fold higher molar concentration. The active molecule is identical — only the dose, formulation buffer and injection volume change. The European Medicines Agency licensed the 8mg dose for neovascular (wet) AMD and diabetic macular oedema in late 2024, with UK MHRA marketing authorisation following and NICE technology appraisal recommending it as a cost-effective option through patient access schemes.

The clinical rationale for 8mg is straightforward: higher intra-vitreal drug concentration takes longer to fall below the therapeutic threshold for VEGF suppression, so the injection-free interval before disease re-activates is longer. In the PULSAR trial for wet AMD, 79% of patients on the 8mg q12 arm maintained 12-week dosing through week 48, and 77% of the q16 arm maintained 16-week dosing — intervals that are physiologically impossible with the 2mg dose, where pharmacokinetic studies suggest functional VEGF rebound by week 6–8 in most eyes.

Crucially, the 8mg dose was non-inferior on best-corrected visual acuity (BCVA) gain at 48 weeks (PULSAR primary endpoint), with comparable rates of intra-retinal and sub-retinal fluid resolution on OCT. This is the foundation of the ‘same vision, fewer visits’ positioning. The PHOTON trial reproduced the result for diabetic macular oedema, with non-inferior BCVA at week 48 against 2mg aflibercept on the standard q8 schedule.

Practically, Eylea HD is given by intravitreal injection — the same procedure as any anti-VEGF agent. The surface of the eye is cleaned with dilute povidone-iodine, the lid is held open with a wire speculum, topical anaesthetic drops are instilled, and the consultant injects 0.07ml through the pars plana 3.5–4.0mm posterior to the limbus using a 30G needle. The injection itself takes seconds; total chair time including OCT, consent recheck and the brief post-injection IOP/visual confirmation is 25–35 minutes. You can read more about the underlying condition on our wet AMD guide and treatment approach on our anti-VEGF wet AMD injection page.

UK 2026 Eylea HD pricing, in detail

Most UK private retinal clinics quote Eylea HD as an all-in episode fee covering the drug vial, the sterile injection room, the consultant’s professional fee, OCT imaging on the day and a 1–2 week safety review. The split between drug cost and clinic fee varies by provider but the all-in figure is what matters to a self-pay patient. Below are the typical UK 2026 self-pay options.

Related fees that may be itemised separately: an initial consultation with a medical retina consultant is £225–£350 (slit-lamp, dilated fundoscopy and consultant time); OCT + OCT-angiography imaging £180–£280; fundus fluorescein angiography, if required, £220–£380 (reserved for diagnostic uncertainty); the Eylea HD 8mg vial drug-only cost is £750–£1,000 under the UK patient access scheme (rarely sold drug-only on the private pathway); a treat-and-extend OCT review without injection is £220–£380; and the 7–10 day safety check is often included (£120–£180 if billed). Bilateral same-day injection is feasible at most centres but priced as two episodes. You can spread the cost with 0% finance.

What a quality UK Eylea HD package should include

When you read a private quote for Eylea HD, check it explicitly covers each of the following — if any line is excluded you will pay it on top.

• Consultant medical retina specialist — GMC-registered consultant ophthalmologist with a completed vitreoretinal or medical retina fellowship and a substantive NHS retina post; not a senior fellow alone.
• Genuine Eylea HD 8mg pre-filled syringe — Bayer/Regeneron-supplied 0.07ml pre-filled syringe with full UK MHRA traceability and intact cold-chain documentation.
• Same-week appointment — wet AMD is sight-threatening; expect a consultation and OCT within 5–7 working days of contact, not 4 weeks.
• Heidelberg or Cirrus HD-OCT imaging on the day — pre-injection OCT to confirm activity (intra-retinal or sub-retinal fluid, pigment epithelial detachment) and post-loading OCT to confirm fluid resolution.
• OCT-angiography on indication — non-invasive imaging of the choroidal neovascular membrane, useful at diagnosis and on treatment change.
• Sterile clean-injection room with HEPA filtration — a CQC-registered ophthalmic day-case room, not a generic clinic; positive-pressure HEPA filtration reduces airborne contaminants.
• Dilute povidone-iodine 5–10% surface prep — the single most evidence-based prophylactic step against endophthalmitis.
• Topical anaesthetic and lid speculum — proxymetacaine plus oxybuprocaine or amethocaine; a wire speculum to prevent lash contamination.
• Post-injection IOP check and visual confirmation — immediate hand-movements or count-fingers vision confirmation; tonometry if a symptomatic IOP spike.
• Safety net for endophthalmitis — a written 24/7 contact pathway to a vitreoretinal on-call surgeon and an out-of-hours route to vitreous tap-and-inject.
• Written treat-and-extend plan — a documented OCT-based extension protocol: q8 to q12 to q16 in 4-week increments if dry; pull back 4 weeks if recurrence.
• Bilateral pathway if needed — many wet AMD patients develop second-eye disease; the package should accommodate bilateral same-day or alternating-eye injection.
• Transparent itemised invoice for your insurer — Bupa, AXA, Aviva, Vitality and WPA need procedure codes (CCSD) and drug-by-batch detail; the clinic should issue this without prompting.

Evidence base — what the Eylea HD literature shows

The 8mg dose is one of the most thoroughly trialled anti-VEGF developments of the past decade, with consistent 96-week and now 2-year readouts.

• PULSAR (wet AMD, 2024) — phase 3 RCT, 1,009 patients, randomised 1:1:1 to 2mg q8, 8mg q12 and 8mg q16; published in The Lancet 2024. The 8mg arms were non-inferior on BCVA at week 48; 79% maintained q12 and 77% maintained q16 dosing.
• PHOTON (DME, 2024) — phase 3 RCT in diabetic macular oedema, 658 patients; 8mg q12/q16 non-inferior to 2mg q8 on BCVA at week 48.
• 96-week PULSAR readout — extended dosing maintained at 96 weeks in >75% of eyes on q12 and ~70% on q16 with no new safety signal.
• NICE TA appraisal — NICE evaluated aflibercept 8mg under technology appraisal pathways for wet AMD and DME and accepted it as a cost-effective option through the Bayer patient access scheme.
• Royal College of Ophthalmologists guideline — the RCOphth wet AMD clinical guideline supports treat-and-extend as a routine maintenance protocol after loading.
• Aflibercept molecular pharmacology — Stewart MW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF.
• Real-world endophthalmitis rate — pooled meta-analyses across all anti-VEGF agents place injection-related endophthalmitis at ~1 in 2,000–3,000 injections with strict dilute povidone-iodine prophylaxis.
• CATT and IVAN comparator trials — foundational head-to-head data for ranibizumab versus bevacizumab informing modern anti-VEGF practice.
• Treat-and-extend evidence — multiple TREX-style protocols (TREX-AMD, ALTAIR, ARIES) demonstrate non-inferior outcomes with fewer injections versus monthly or pro re nata dosing.
• HAWK and HARRIER (brolucizumab) — comparator evidence for high-volume anti-VEGF; a subsequent IOI signal reshaped how new high-dose agents are monitored.
• UK Macular Society patient outcomes data — patient-reported outcomes after wet AMD treatment in the UK private and NHS pathways.

Eylea HD versus the other anti-VEGF options

Choosing between anti-VEGF agents in 2026 is no longer a binary question. Each agent offers a different combination of evidence, dosing interval, mechanism and price.

• Standard Eylea (aflibercept 2mg) — the benchmark molecule with a decade of safety data and q8 dosing after loading. Cheaper per dose than Eylea HD but typically requires more visits; identical safety profile.
• Vabysmo (faricimab 6mg) — a dual Ang-2/VEGF-A inhibitor licensed for wet AMD and DME with q12–q16 extension data from TENAYA/LUCERNE and YOSEMITE/RHINE. A direct alternative to Eylea HD; choice often comes down to clinician preference and prior response. Compare costs on our Vabysmo wet AMD injection page.
• Lucentis (ranibizumab 0.5mg) — the original anti-VEGF for wet AMD with extensive 15-year safety data; typically monthly or treat-and-extend q4–q12 dosing. Now usually reserved when newer agents fail or are contraindicated.
• Biosimilar ranibizumab — several MHRA-licensed biosimilars (Byooviz, Ximluci, Ongavia) offer ranibizumab equivalents at lower drug cost; useful where insurer formularies dictate.
• Beovu (brolucizumab) — a compact molecule allowing a high molar dose; affected by a post-marketing IOI/retinal vasculitis safety signal that has restricted clinical use.
• Off-label bevacizumab (Avastin) — widely used internationally for cost reasons; not licensed for intraocular use in the UK and not offered on most private retina pathways.
• Photodynamic therapy with verteporfin — reserved for polypoidal choroidal vasculopathy variants and chronic central serous chorioretinopathy; not first-line for typical wet AMD.
• Geographic atrophy (advanced dry AMD) — a different disease from wet AMD, not treated with anti-VEGF injections. There is currently no licensed medication for geographic atrophy in the UK; management focuses on monitoring, AREDS2-type supplements, smoking cessation and low-vision support. See our macular degeneration prices guide.
• No treatment / observation — untreated wet AMD progresses to disciform scar and central scotoma over 12–24 months in the majority of eyes; observation is rarely defensible once subretinal fluid or haemorrhage is documented.

Who is private Eylea HD the right choice for?

Eylea HD is licensed and clinically indicated for the conditions below, and the private pathway is particularly attractive when NHS treat-and-extend intervals are slipping.

• Newly diagnosed wet AMD — OCT or OCT-A confirming an active choroidal neovascular membrane with intra-retinal or sub-retinal fluid; same-week loading injection is the priority.
• Established wet AMD on standard Eylea 2mg seeking longer intervals — patients who are well-controlled but tired of 6–8 week visits often switch to Eylea HD specifically for q12–q16 dosing.
• Wet AMD with persistent fluid on shorter-interval 2mg dosing — the higher dose can resolve residual fluid in eyes that never fully dry on 2mg; switching trials support this.
• Diabetic macular oedema with vision loss <6/12 — a PHOTON-supported indication; particularly useful in patients juggling diabetic clinic visits.
• Geographically distant from the clinic — patients commuting some distance benefit disproportionately from the q12/q16 schedule.
• Bilateral wet AMD — bilateral disease doubles the injection burden; halving the visit frequency materially improves quality of life.
• Patient on full anticoagulation — anti-VEGF injection is safe to perform on warfarin, DOACs and dual antiplatelet therapy — no stop required.
• Recent insurer change with formulary access — Bupa, AXA, Aviva, Vitality and WPA all now cover aflibercept 8mg under wet AMD pathway codes; private cover often unlocks the agent before NHS funding.
• Anaesthesia-sensitive patients — intravitreal injection is topical only; no general or regional anaesthesia required.
• Post-cataract eyes with developing wet AMD — many wet AMD diagnoses are made at routine post-cataract OCT; the private pathway allows seamless continuation from the cataract surgeon to medical retina.

NHS, private medical insurance and Eylea HD

Eylea HD is available on the NHS under NICE technology appraisal and the Bayer patient access scheme. Wet AMD is one of the more time-pressured eye conditions on the NHS because untreated activity over weeks erodes irrecoverable BCVA. The challenge in the NHS is not eligibility but capacity: anti-VEGF macular clinic slots are some of the most contested in ophthalmology, and a treat-and-extend interval that drifts from the OCT-recommended 8 weeks to 12 or 14 weeks because of clinic pressure undermines exactly the visual stability the regime is designed to maintain.

Private pathways solve the capacity problem. A first injection within 5–7 days of OCT diagnosis is realistic at most CQC-registered retina centres, and the subsequent treat-and-extend rhythm is held strictly to the OCT-recommended interval (q12 or q16) once stability is achieved. For wet AMD in particular, the clinical case for paying privately is not the molecule (which is the same one the NHS provides) but the timing and the visit cadence. Some patients use a hybrid pathway: initiate privately to ensure same-week loading, then transfer to NHS care once treat-and-extend is stable — reasonable provided the receiving NHS unit can honour the same interval the private OCT data has demonstrated.

All five major UK insurers — Bupa, AXA Health, Aviva, Vitality and WPA — cover Eylea HD on their standard pathways, subject to your specific policy benefits, excesses and pre-authorisation requirements. Wet AMD is generally treated as a chronic condition requiring ongoing care; check whether your policy is ‘full refund’ or capped per-condition and whether the chronic-condition exclusion applies. Pre-authorisation generally requires the consultant’s OCT report, evidence of activity (fluid or haemorrhage) and a documented treatment plan — the retina centre’s administrative team usually handles this on your behalf. Our guidance for insured patients explains how to arrange cover.

Risks of intravitreal Eylea HD injection

Intravitreal anti-VEGF injection is one of the most-studied procedures in medicine; the absolute risks are low but not zero. The 8mg dose has a safety profile broadly comparable to 2mg aflibercept in pooled trial data.

• Endophthalmitis — ~1 in 2,000–3,000 injections with dilute povidone-iodine prophylaxis. Presents at 2–7 days post-injection with pain, vision loss and hypopyon; needs same-day vitreoretinal review and tap-and-inject.
• Sterile intraocular inflammation (IOI) — mild anterior uveitis or vitritis in <1% of eyes; usually responds to topical steroid. Rare cases of retinal vasculitis are reported across the anti-VEGF class.
• Sub-conjunctival haemorrhage — a painless red patch at the injection site; common (15–30%) and harmless, resolving over 1–2 weeks.
• Transient intraocular pressure spike — IOP can rise briefly after the 0.07ml volume injection; a significant spike requiring intervention is rare with good chair-side technique.
• Floaters — air or vitreous strand floaters are common immediately post-injection and settle within hours to days.
• Retinal detachment — <1 in 5,000 injections; presents with new flashes, floaters or a curtain visual field defect.
• Arterial thromboembolic events (theoretical) — pooled MACE rates across anti-VEGF trials are comparable to control, but caution remains in patients within 3 months of stroke or MI.
• Failure of disease response — a minority of eyes do not dry on 8mg dosing; the next step is usually switching anti-VEGF agent (typically to Vabysmo) rather than dose escalation.
• Patient adherence drop-off — the biggest real-world cause of vision loss in treated wet AMD is missed appointments; longer intervals only help if the patient still attends at week 16.

Recovery after an Eylea HD injection

There is no formal recovery period after intravitreal Eylea HD. Most patients are out of the chair within 30 minutes of arrival and resume normal activities the same day. Reading, screen work, light exercise and stairs are all unrestricted on day 1. The eye is not patched, but pupil-dilation drops may have been instilled, so many patients arrange a companion driver for the first injection until they know how they respond.

In the first 24 hours patients commonly notice a small dark floater (an air bubble or proteinaceous fragment), a foreign-body sensation from the povidone-iodine prep, and a bright red sub-conjunctival haemorrhage at the injection site. None of these is concerning; the floater settles within hours, the foreign-body sensation responds to preservative-free lubricants, and the haemorrhage clears over 1–2 weeks. For the first 48 hours avoid swimming, hot tubs, dusty environments and rubbing the eye; switch from contact lenses to glasses.

Red-flag symptoms to escalate to the 24/7 clinic line immediately: progressively worsening vision over 1–3 days, increasing pain not relieved by simple analgesia, increasing redness, a hypopyon (visible white fluid level in the front of the eye), or new floaters, flashes or a curtain field defect at any point. The next milestone is your week 1–2 safety check, followed by an OCT review at the planned treat-and-extend interval — typically 8 weeks after the third loading dose, extending to 12 and then 16 weeks if the macula is dry.

Frequently asked questions